MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-02-2026
Cerus Corporation DPO Ratio 2011-2026 | CERS
Annual DPO Ratio Cerus Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | 242 | 215 | 178 | 154 | 81.2 | 170 | 91.6 | 127 | 92.2 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 242 | 81.2 | 150 |
Quarterly DPO Ratio Cerus Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | 148 | 159 | 192 | - | 202 | 228 | 254 | - | 267 | 250 | 221 | - | 208 | 220 | 184 | - | 187 | 230 | - | - | - | - | - | - | 85.6 | - | - | - | 158 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 267 | 85.6 | 200 |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Amphastar Pharmaceuticals
AMPH
|
31.7 | $ 21.75 | 1.59 % | $ 1.02 B |  USA |
 |
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
405 | $ 0.91 | 1.61 % | $ 6.69 M | China |
 |
ACADIA Pharmaceuticals
ACAD
|
75.2 | $ 22.29 | 1.5 % | $ 3.69 B | USA |
 |
Advaxis
ADXS
|
143 K | - | -9.65 % | $ 45.9 M | USA |
 |
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | USA |
 |
Ampio Pharmaceuticals
AMPE
|
2.85 K | - | -11.43 % | $ 502 K | USA |
 |
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - |  Russia |
 |
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
9.04 K | - | -10.17 % | $ 12.2 K | USA |
 |
Aquestive Therapeutics
AQST
|
395 | $ 4.1 | 0.37 % | $ 438 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
133 | $ 23.2 | -0.26 % | $ 2.95 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M |  Israel |
 |
Autolus Therapeutics plc
AUTL
|
9.57 | $ 1.42 | -1.39 % | $ 378 M | Britain |
 |
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | Britain |
 |
BioDelivery Sciences International
BDSI
|
96.3 | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
915 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
182 | - | - | $ 546 M | USA |
 |
ContraFect Corporation
CFRX
|
1.83 K | - | -5.16 % | $ 5.39 M | USA |
 |
Cardiff Oncology
CRDF
|
406 | $ 1.72 | -0.29 % | $ 115 M | USA |
 |
BioXcel Therapeutics
BTAI
|
34.2 K | $ 1.07 | 0.94 % | $ 13.1 M | USA |
 |
Esperion Therapeutics
ESPR
|
7.93 K | $ 1.95 | 1.83 % | $ 405 M | USA |
 |
CASI Pharmaceuticals
CASI
|
123 | - | - | $ 35.4 M | USA |